About the API
Montelukast sodium is an orally active compound that belongs to a class of molecules termed leukotriene receptor antagonists (LTRAs) and is approved for the treatment of symptoms related to asthma and allergic rhinitis (hay fever). It is also prescribed to prevent exercise-induced bronchospasm. Montelukast sodium inhibits the binding of leukotrienes (molecules secreted by white blood cells) to a receptor that triggers an inflammatory response. Due to its mechanism of action, this drug is not prescribed for the treatment of acute asthma attacks.
Montelukast sodium became FDA approved for the treatment of asthma, allergic rhinitis, and exercise-induced bronchoconstriction under the trade name Singulair in 1998. It is currently manufactured through large-scale synthetic organic chemistry methods starting from simple, commercially available precursors.